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Second Best Medical Therapy
P. Burns, E. Lima and A. W. Bradbury
University Department of Vascular Surgery, Heartlands Hospital, Birmingham, U.K.
Background: best medical therapy (BMT) provides patients with peripheral arterial disease (PAD) substantial protection
against future vascular events.
Objective: to determine the quality of BMT received by PAD patients in this vascular surgery unit.
Methods: retrospective case-note review of 50 consecutive patients in each of the following groups: intermittent claudica-
tion (out-patients), symptomatic carotid artery disease (out-patients), lower limb angioplasty, lower limb bypass surgery,
carotid endarterectomy.
Results: overall BMT use was poor. Fifteen percent of smokers had assistance with smoking cessation noted. Seventy-eight
percent of patients were taking an antiplatelet agent, 38% cholesterol-lowering medication and 51% antihypertensive
medication. Fifty-three percent of patients had a cholesterol measurement, 50% of out-patients had a blood pressure
measurement and 53% of non-diabetics had a random blood glucose performed. Sixteen of the patients with lower limb
disease were given advice about exercise. Patients with a history of coronary artery disease were more likely to be taking
cholesterol lowering, or antihypertensive medication.
Conclusions: BMT is poorly used in patients with PAD, which will result in an excess of cardiovascular morbidity and
mortality. Strategies need to be developed to increase the use of BMT in our patients.
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Peripheral arterial disease (PAD) affects appro-
ximately 20% of the adult population; is the common-
est single cause of stroke, major amputation and
non-cardiac sudden death; and is also associated
with a marked (3±4 fold) increase in cardiac morbidity
and mortality due to co-existing coronary artery dis-
ease (CAD).1 Best medical therapy (BMT) (comprising
principally of smoking cessation strategies, cholesterol
lowering, blood pressure control, diagnosis and con-
trol of diabetes mellitus (DM), prescription of an anti-
platelet agent and exercise therapy) has long been
recognised as the cornerstone of management for
patients with CAD because it leads to a very substan-
tial reduction in future vascular events and is highly
cost-effective.2 Although it is overwhelmingly likely
that BMT would offer the same degree of protection to
patients with PAD,3 it has been suggested that many
such patients go untreated.4±7 The aim of this study
was to determine the quality of BMT provided toPlease address all correspondence to: A. W. Bradbury, Professor of
Vascular Surgery, Lincoln House (Research Institute), Birmingham
Heartland, Hospital, Bordesley Green East, Birmingham,
B9 5SS, U.K.
1078±5884/02/050400 05 $35.00/0 # 2002 Elsevier Science Ltd. Allpatients with PAD presenting to a hospital based
vascular surgery unit.
Methods
This was a retrospective case-note review of 50 conse-
cutive patients in each of the following groups:
(1) Patients presenting for the first time to clinic
with intermittent claudication (IC), (2) patients pre-
senting for the first time to clinic with symptomatic
carotid artery disease, (3) patients undergoing percu-
taneous balloon angioplasty (PTA) of the lower
limb arteries, (4) patients undergoing lower limb
bypass surgery, and (5) patients undergoing carotid
endarterectomy (CEA).
The institution of each component of BMT (smoking
cessation, antiplatelet agent use, cholesterol lowering
therapy, blood pressure control, diagnosis of diabetes
mellitus and exercise therapy) at the end of each fini-
shed hospital episode (out-patient visit or in-patient
stay) was recorded. For the purposes of the study
hypercholesterolaemia was defined as a total serum
cholesterol 45.5 mmol/l, an abnormal random blood
glucose was defined as 47 mmol/l, and hypertension
as a blood pressure (BP) greater than 160/90 mmHg.rights reserved.
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Fig. 2. Noted antiplatelet agent use.
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Smoking cessation
Almost half (118/250, 47%) of the patients were cur-
rent smokers and a further 57 (23%) were ex-smokers
(43 months). Surprisingly, in 35 (14%) cases there was
no mention of smoking status or history in the case
records (Fig. 1). Seventy-two of the 150 patients under-
going invasive treatment were still smoking. Details of
smoking cessation advice or therapy were recorded in
the notes of only 17 patients, and only one patient was
recommended to start on nicotine replacement ther-
apy. No use was made of written advice, or of the
locally provided smoking cessation classes.
Antiplatelet agent (APA) use
Prescription of an APA was noted in the records of
196 patients (78%). Of the 54 patients apparently not
taking an APA, 13 had a contra-indication to APA
therapy because of aspirin or clopidogrel intolerance,
or the use of warfarin (Fig. 2). This means that 29 (20%)
of the 150 patients undergoing intervention (PBA,
bypass or CEA) were not on an APA at the time of
their procedure. Patients with lower limb disease were
less likely to be taking an antiplatelet agent than
patients with carotid artery (73% vs 97% p5 0.001
w2 test ± excluding those who were not appropriate
for an APA).
Treatment of hypercholesterolaemia
Ninety-six (38%) patients were receiving cholesterol-
lowering therapy prior to their contact with the
vascular surgery service. Cholesterol was measured
in only 133 (53%) patients during their vascular
surgery consultant episode. Interestingly, cholesterol0%
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Fig. 1. Smoking status.was more likely to be measured in patients who were
already on some form of cholesterol-lowering therapy
(60/96, 63%) than in those patients who were not (73/
154, 47%, p5 0.02) (Fig. 3). The median (interquartile
range, [IQR]) cholesterol of those who did have their
cholesterol measured was 5.5 (5.1±6) mmol/l for those
who were already on cholesterol-lowering treatment
and 5.3 (4.6±6.7) mmol/l for those who were not
(pNS). Expressed in another way, 32 of the 60 who
were on cholesterol-lowering therapy and had their
cholesterol remeasured still had a total cholesterol
45.5 mmol/l compared with 22 of 73 patients who
had their cholesterol measured and were not already
on treatment (p 0.007).Cholesterol
lowering
medication
altered
9
Cholesterol
>5.5
32
Cholesterol
lowering
medication
altered
6
Cholesterol
>5.5
22
Fig. 3. Flow chart showing number of patients on cholesterol low-
ering therapy at time of consultation, and whether cholesterol was
checked, results, and actions.
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terolaemia, either on (n 32) or off (n 22) treatment,
new or altered lipid lowering therapy was instituted
in 15. Taken together these data mean that 110 of
the 150 patients undergoing intervention (PBA,
bypass or CEA) had either not be screened or treated,
or were on inadequate treatment for hypercholester-
olaemia (cholesterol still 45.5 mmol/l) at the time of
their procedure.
Diabetes screening
Sixty-two (25%) patients were known to be diabetic.
Of the remainder, 99 (53%) were screened for diabetes,
all by random blood glucose, revealing 20 abnormal-
ities (random blood glucose 47 mmol/l). No out-
patients (n 4) had an abnormality acted upon; 6 of
16 in-patients with a high random blood glucose had
the result investigated (test repeated, oral glucose
tolerance test, or diabetic referral) (Fig. 4).
Exercise therapy
There is no supervised exercise programme available
at our unit. Ten (7%) patients with lower limb disease
were noted to have been given general advice on
exercise (i.e. `` keep walking''), 6 (4%) patients were
noted to have been given specific exercise advice
(`` walk for 30 min, 3 times per week, walking to the
point of maximum claudication before stopping'').Test repeated;
OGTT; or
diabetic
referral
6
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Fig. 4. Number of non-diabetic patients who were screened for DM;
found to have an abnormal result, and whether high results were
acted upon. OGTTOral glucose tolerance test.
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One hundred and twenty-seven (51%) patients were
already receiving anti-hypertensive treatment. All in-
patients had their BP measured on admissions (data
not shown). Less than 50% of out-patients had their
BP checked, and few patients had abnormal blood
pressure results acted upon (Fig. 5).
Influence of CAD
Fifty-nine (24%) patients had a history of CAD
(angina, myocardial infarction or coronary artery sur-
gery). These patients were more likely to be taking
cholesterol lowering, or anti-hypertensive medication
at their consultation. However, a history of CAD did
not seem to influence vascular surgeons in whether
patients were screened for hypercholesterolaemia,
hypertension or diabetes (Table 1). Similar proportions
from each group were taking an antiplatelet agent
when seen.
Discussion
The inescapable conclusion to be drawn from this
study is that PAD patients going through this vascular
surgery unit have not been receiving BMT, including a
significant proportion of patients undergoing surgical
or endovascular procedures. This is despite compel-
ling `` level 1'' evidence indicating that BMT offersResult advised
to GP /
medication
altered
0
BP > 160/90
13
BP checked
92
On anti-
hypertensive
therapy
127
Result advised
to GP /
medication
altered
1
BP > 160/90
16
BP checked
97
Not on anti-
hypertensive
therapy
123
Fig. 5. Flow chart showing number of patients receiving antihyper-
tensive medication, and the number who had their BP checked,
found to be high, and acted upon.
Table 1. Comparison of BMT between patients with and without
a history of CAD.
History of
CAD (%)
(n 59)
No history
of CAD (%)
(n 191)
p
(2 test)
Taking antiplatelet therapy 49 (83) 141 (74) 0.32
Taking cholesterol
lowering therapy
34 (58) 51 (27) 50.001
Cholesterol checked 27 (46) 105 (55) 0.19
Taking anti-hypertensive
therapy
38 (64) 88 (46) 0.02
BP checked 46 (78) 143 (75) 0.63
Screened for DM 25 (56) 74 (52) 0.66
Non-diabetics only, n 188 (CAD n 45, non-CAD n 143).
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cular events.8 Failure to implement BMT in our
patients has almost certainly, therefore, led to excess
morbidity and possibly mortality.
Retrospective case-note review has inescapable
drawbacks, in that if information is not recorded (for
example smoking advice), then it will appear that the
issue has been ignored. This was minimised by care-
fully searching all available sources of information
(handwritten notes, GP letters, dictated letters to
GPs). In addition, for many aspects of BMT, particu-
larly for in-patients, objective evidence was available
of their use (drug prescription charts, observation
charts, computerised blood results). Therefore, we
believe the data to be sufficiently robust to be of use.
Present data echo the findings of several other
groups suggesting that this is a widespread prob-
lem.4±7 But why does it happen? There are a number
of possible reasons but, perhaps most importantly,
research into the benefits of BMT in PAD patients
has lagged far behind that directed towards symptom-
atic CAD and only recently have data showing the
benefit of BMT in PAD patients have become avail-
able. In addition, there has been a lack of awareness of
the cardiovascular risk faced by PAD and, conse-
quently, a belief that the costs of instituting BMT in
patients with PAD could not be justified. For these
reasons, rather than viewing the PAD patient in a
holistic manner, those treating PAD have tended to
focus on the arterial lesion and its surgical or endo-
vascular (angioplasty, stenting) treatment. But such
interventions are expensive, potentially hazardous,
of limited durability and do not impact upon the
patients' underling vascular risk.9,10 By contrast, BMT
dramatically reduces that vascular risk,3 can improve
functional status and quality of life in the long
term,11,12 is relatively inexpensive and virtually free
from risk.Present data have highlighted specific failings in
current management:
(a) Failure to make use of proven anti-smoking
therapy such as NRT,13 bupropion14 and specialist
counselling.15
(b) Failure to make sure that all patients receive an
APA8,16,17 and, in particular, to make use of alter-
natives to aspirin.18
(c) Failure to measure cholesterol and institute
cholesterol-lowering therapy.3
(d) Failure to make sure that patients already on
cholesterol-lowering therapy are being treated
adequately to target.
(e) Failure to implement a consistent evidence-based
policy with regard to BP.2,19
(f) Failure to screen for diabetes. Only half of those
patients not already known to be diabetic had
their blood glucose measured and only a quarter
of those with an abnormal result went on to have
any further action taken.
(g) Failure to make available a structured exercise
programme.20,21 Almost three-quarters of the
patients undergoing PTA were being treated for
IC and less than 10% of these patients had been
offered any form of exercise therapy, despite ran-
domised controlled trial evidence that this is an
effective therapy.9,10
It is strange but true to note that even in the U.K.'s
hard-pressed National Health Service (NHS) it is still
easier for a vascular surgeon to refer a claudicant for
angioplasty (despite the attendant cost, risk, and lack
of durability) than it is to ensure that the patient
undergoes a full life-style evaluation, modification of
risk factors and institution of BMT. In order to over-
come the very serious deficiencies that are identified
in this study, and which we believe are representative
of the standard of care provided in most U.K. NHS
hospitals, vascular surgeons and interventionalists
must re-think the way they approach the management
of PAD and re-organise their services accordingly.
Vascular medicine specialists, or angiologists, are
more common in the rest of Europe than the U.K.,
and it would be interesting to see whether this has
an influence on the institution of BMT. In the U.K., it
may be more achievable to have nurse specialists
working in protocol-driven vascular risk factor clinics
working closely with colleagues in primary care can
make sure that patients do not `` slip through the net''.
This is exactly what we are now implementing in
response to the data presented in this paper; an
attempt to truly close the audit loop. In the longer
term, it is hoped that as BMT receives more emphasisEur J Vasc Endovasc Surg Vol 24, November 2002
404 P. Burns et al.in vascular surgery teaching, it will be instituted more
completely.
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